Wissenschaftliche Publikationen

  • Czapiewski P, Cornelius M, Hartig R, Kalinski T, Haybaeck J, Dittmer A, Dittmer J, Ignatov A, Nass N. Virchows Arch. 2022 Jan 12. doi: 10.1007/s00428-021-03238-8. Online ahead of print.PMID: 35020071
  • The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer. Pieper W, Ignatov A, Kalinski T, Haybaeck J, Czapiewski P, Nass N. Cancer Biomark. 2021 May 28. doi: 10.3233/CBM-203127. Online ahead of print.PMID: 34092612
  • Salvage Radiation Therapy for Patients With Relapsing Glioblastoma Multiforme and the Role of Slow Fractionation.
  • Ciernik IF, Gager Y, Renner C, Spieker S, Arndt N, Neumann K. Front Oncol. 2020 Dec 8;10:577443. doi: 10.3389/fonc.2020.577443. eCollection 2020
  • The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.
  • Golden E, Rashwan R, Woodward EA, Sgro A, Wang E, Sorolla A, Waryah C, Tie WJ, Cuyàs E, Ratajska M, Kardaś I, Kozlowski P, Johnstone EKM, See HB, Duffy C, Parry J, Lagerborg KA, Czapiewski P, Menendez JA, Gorczyński A, Wasag B, Pfleger KDG, Curtis C, Lee BK, Kim J, Cursons J, Pavlos NJ, Biernat W, Jain M, Woo AJ, Redfern A, Blancafort P. Nat Commun. 2021 Mar 26;12(1):1920. doi: 10.1038/s41467-021-22101-7.
  • Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma.
  • Skofler C, Kleinegger F, Krassnig S, Birkl-Toeglhofer AM, Singer G, Till H, Benesch M, Cencic R, Porco JA Jr, Pelletier J, Castellani C, Raicht A, Izycka-Swieszewska E, Czapiewski P, Haybaeck J.Cells. 2021 Feb 2;10(2):301. doi: 10.3390/cells10020301.
  • Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma.
  • Skofler C, Kleinegger F, Krassnig S, Birkl-Toeglhofer AM, Singer G, Till H, Benesch M, Cencic R, Porco JA Jr, Pelletier J, Castellani C, Raicht A, Izycka-Swieszewska E, Czapiewski P, Haybaeck J.Cells. 2021 Feb 2;10(2):301. doi: 10.3390/cells10020301.
  • Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.
  • Linke C, Wösle M, Harder A.BMC Cancer. 2020 Sep 18;20(1):896. doi: 10.1186/s12885-020-07397-w.
  • Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma.
  • Kunc M, Gabrych A, Rękawiecki B, Gorczyński A, Haybaeck J, Biernat W, Czapiewski P.Contemp Oncol (Pozn). 2020;24(1):1-4. doi: 10.5114/wo.2020.94718. Epub 2020 Mar 30.
  • MLH1 promoter hypermethylation in uterine carcinosarcoma rarely coexists with TP53 mutation.
  • Kunc M, Gabrych A, Rekawiecki B, Gorczynski A, Franke S, Haybaeck J, Biernat W, Czapiewski P.Contemp Oncol (Pozn). 2019;23(4):202-207. doi: 10.5114/wo.2019.89635. Epub 2019 Nov 7.
  • Monoclonal antibodies therapy for Covid-19 - Experiences at a regional hospital. Judith Pannier, Norbert Nass, Gerhard Behre. doi: https://doi.org/10.1101/2021.09.22.21263488 
  • The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: a retrospective analysis. Jan-Hendrik Maiwald, Susanne Sprung, Piotr Czapiewski, Wiebke Lessel, Anna Scherping, Dirk Schomburg, Markus Plaumann, Bartłomiej Tomasik, Gerhard Behre, Johannes Haybaeck, Atanas Ignatov, Holm Eggemann, Norbert Nass. Contemp Oncol (Pozn) 2021; 25 (3): 204–212. DOI: https://doi.org/10.5114/wo.2021.110010
     

https://pubmed.ncbi.nlm.nih.gov/31639216/